

March 14, 2018



## Veru to Present at the Oppenheimer 28th Annual Healthcare Conference on March 21, 2018

MIAMI, March 14, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU) today announced that the company will present at the Oppenheimer 28<sup>th</sup> Annual Healthcare Conference at 1:35 p.m. ET on Wednesday, March 21, 2018 at the Westin New York Grand Central, in New York City.

A webcast of the presentation will be available at [www.verupharma.com](http://www.verupharma.com). The presentation will be archived and accessible on the web site for at least 90 days.

### **About Veru Inc.**

Veru Inc. (Veru) is a biopharmaceutical company focused on urology and oncology. The company is currently developing drug product candidates: Tamsulosin DRS, slow release granules, and Tamsulosin XR capsules for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) (NDA planned 2018), Solifenacin DRG, slow release granules, for overactive bladder (urge incontinence, urgency and frequency of urination) (NDA planned 2019), Tadalafil/finasteride combination capsule for restricted urination because of an enlarged prostate (NDA planned 2019), VERU-944 (cis-clomiphene citrate) for hot flashes in men associated with prostate cancer hormone treatment (planned Phase 2 in 2018), and VERU-111 a novel oral anti-tubulin cancer therapy targeting alpha & beta tubulin for a variety of malignancies, including metastatic prostate, breast, endometrial and ovarian cancers (planned Phase 1/2 in 2018).

To help support these clinical development programs, the company markets and sells the PREBOOST<sup>®</sup> medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation which is being co-promoted with Timm Medical Technologies, Inc. and the FC2 Female Condom<sup>®</sup> (now available by prescription in the US including through the virtual doctor smartphone app "HeyDoctor" at [www.fc2.us.com](http://www.fc2.us.com)) in the United States and through The Female Health Company Division in the Global Public Health Sector. The Female Health Company Division markets to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. More information about Veru and its products can be found at [www.verupharma.com](http://www.verupharma.com), [www.PREBOOST.com](http://www.PREBOOST.com), [www.fc2.us.com](http://www.fc2.us.com) and [www.fc2femalecondom.com](http://www.fc2femalecondom.com). For corporate and investor-related information about the Company, please visit <https://verupharma.com/investors>.

Contact:  
Kevin Gilbert

786-322-2213



Source: Veru Inc.